SCHEMBL2491929

SCHEMBL2491929

CCc1ccc(C(c2ccc(CC)cc2)c2ccc(CC)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.58
MAPK1 P28482 1/20 0.58
ATM Q13315 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TP53 P04637 1/20 0.48
TAAR1 Q96RJ0 1/20 0.46
CYP2A6 P11509 1/20 0.44
LPL P06858 1/20 0.44
LIPG Q9Y5X9 1/20 0.44
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
CA2 P00918 1/20 0.41
LMNA P02545 2/20 0.39
PLAU P00749 1/20 0.39
TRPA1 O75762 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14361867 0.90 TP53 (0.59) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL31409202 0.88 TSHR (0.48) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL7919067 0.88 ESR1 (0.53) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL14018688 0.84 SLC2A1 (0.55) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL19324885 0.84 SLC2A1 (0.55) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL19324608 0.82 GRK6 (0.49) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL36295 0.80 TP53 (0.67) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL500563 0.80 TSHR (0.56) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL139408 0.80 L3MBTL1 (0.56) TSHRMAPK1ATMTDP1L3MBTL1
SCHEMBL19622539 0.79 L3MBTL1 (0.41) TSHRMAPK1ATMTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7232634-B2 Charge generating layer and a charge transport layer with bulky organic groups to prevent recrystallization of the charge transport molecule and shield the nitrogen from molecular attack; oxidation reisitance, wear resistance XEROX CORPORATION (US) 2007-06-19 US claimed
EP-2380567-B1 MELANIN PRODUCTION INHIBITOR POLA CHEM IND INC (JP) 2019-01-16 EP disclosed
EP-3009123-A1 MELANIN PRODUCTION INHIBITOR Pola Chemical Industries Inc. (JP) 2016-04-20 EP disclosed
US-20150328107-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2015-11-19 US disclosed
EP-2845587-A2 Melanin production inhibitor Pola Chemical Industries Inc. (JP) 2015-03-11 EP disclosed
US-20140363389-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2014-12-11 US disclosed
US-8846012-B2 Melanin production inhibitor POLA CHEMICAL INDUSTRIES INC. (JP) 2014-09-30 US disclosed
EP-2380567-A1 MELANIN PRODUCTION INHIBITOR Pola Chemical Industries Inc. (JP) 2011-10-26 EP disclosed
US-20110243865-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2011-10-06 US disclosed
US-7232634-B2 Charge generating layer and a charge transport layer with bulky organic groups to prevent recrystallization of the charge transport molecule and shield the nitrogen from molecular attack; oxidation reisitance, wear resistance XEROX CORPORATION (US) 2007-06-19 US disclosed
US-20060068309-A1 Imaging member XEROX CORPORATION 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110243865-A1 MELANIN PRODUCTION INHIBITOR TYR, F12, TH TSHR 100/4885MAPK1 172/4885ATM 2913/4885
US-20150328107-A1 MELANIN PRODUCTION INHIBITOR TYR, MC1R, F12 TSHR 75/4885MAPK1 221/4885ATM 2976/4885
US-20140363389-A1 MELANIN PRODUCTION INHIBITOR TYR, F12, MC1R TSHR 68/4885MAPK1 194/4885ATM 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.